Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014733
Filing Date
2023-08-14
Accepted
2023-08-14 09:15:44
Documents
68
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvlp-20230630x10q.htm   iXBRL 10-Q 1355420
2 EX-10.1 rvlp-20230630xex10d1.htm EX-10.1 121537
3 EX-31.1 rvlp-20230630xex31d1.htm EX-31.1 11172
4 EX-32.1 rvlp-20230630xex32d1.htm EX-32.1 8017
  Complete submission text file 0001558370-23-014733.txt   5724039

Data Files

Seq Description Document Type Size
5 EX-101.SCH rvlp-20230630.xsd EX-101.SCH 46633
6 EX-101.CAL rvlp-20230630_cal.xml EX-101.CAL 50444
7 EX-101.DEF rvlp-20230630_def.xml EX-101.DEF 159481
8 EX-101.LAB rvlp-20230630_lab.xml EX-101.LAB 376699
9 EX-101.PRE rvlp-20230630_pre.xml EX-101.PRE 272663
62 EXTRACTED XBRL INSTANCE DOCUMENT rvlp-20230630x10q_htm.xml XML 887676
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Filer) CIK: 0001739426 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38709 | Film No.: 231166721
SIC: 2834 Pharmaceutical Preparations